Publication date: February 16, 2026
The European Green Deal has been the subject of much discussion in public debate since its announcement. As part of this ambitious project, the European Commission aimed to achieve, among other things, climate neutrality for the entire European Union by 2050. One of the key aspects of this economic transformation was to focus on more sustainable products and, in particular, a transition to a circular economy. Sustainable products were considered a prerequisite for implementing such an economic model.
More
Publication date: February 12, 2026
The EU Chips Act is a major European legislative package launched to boost the EU’s semiconductor industry, aiming to double its global market share to 20% by 2030, enhance supply chain resilience, and reduce reliance on external chipmakers. The EU Chips Act 2.0 is a proposed follow-up to the 2023 Chips Act, driven by a coalition of EU member states (including Germany, France, Netherlands) in late 2025 to shift from crisis management to long-term industrial strategy. It aims to secure supply chains, boost competitiveness, and accelerate investment by simplifying regulations and targeting R&D.
More
Publication date: February 12, 2026
In recent years, the importance of artificial intelligence (AI) in drug development, evaluation, and monitoring has grown significantly. AI technologies have the potential to accelerate research, improve predictions of drug efficacy and safety, and reduce the need for animal testing. At the same time, their use presents new challenges. AI models can make errors, be susceptible to unforeseen risks, or use data in a non-transparent manner. To fully realize the benefits of AI while minimizing risks, it is essential to establish clear and common principles for the use of these technologies. In response to these challenges, the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) have jointly developed ten principles of good practice for the use of AI in the drug lifecycle. This document is fundamental and a framework, not a binding legal regulation – it provides general directions and guidelines that should guide drug manufacturers, applicants, and regulators. These principles indicate how AI should be designed and used to ensure it is ethical, safe, transparent, and based on reliable data. The ten principles also identify areas where international regulators, standards-setting organizations, and other collaborating entities can work together to promote good practice in drug development. These areas of collaboration include: conducting scientific research, creating educational tools and resources for market participants, international harmonization, and developing consensus standards. To facilitate initial analysis, these principles can be grouped into three logical pillars. Principles 1-3 address organizational foundations and people, focusing on interdisciplinary team expertise and ensuring that AI remains under human control within specific, established governance processes. Principles 4-7 address technical quality and model integrity, addressing the “heart” of the technology. Principles 8-10 address accountability and lifecycle, defining standards for documentation, clear communication with users, and continuous monitoring of the model after its implementation. Below is a detailed summary of the 10 principles of good practice for AI in the drug lifecycle:
More
Publication date: February 6, 2026
Cybersecurity certifications are designed for IT professionals, including system and network administrators, security specialists, engineers, and those aspiring to these roles, to validate their knowledge and practical skills in protecting against digital threats. The certification also covers ICT products, services, and processes, and aims to inform consumers about the level of digital security and support Polish companies in European markets.
On August 28, 2025, the Act of June 25, 2025, on the national cybersecurity certification scheme entered into force, implementing Regulation (EU) 2019/881 of the European Parliament and of the Council of April 17, 2019, on ENISA (the European Union Agency for Cybersecurity) and cybersecurity certification in information and communication technologies, and repealing Regulation (EU) No 526/2013 (Cybersecurity Act) (OJ L 151, 7.06.2019, p. 15 and OJ L 2025/37, 15.01.2025).
More
Publication date: February 6, 2026
In cross-border trade, businesses often opt for alternative dispute resolution (ADR) methods, such as international arbitration. This solution ensures, above all, a more neutral, faster, more flexible, and highly professional procedure. Naturally, in such a situation, the parties do not want to be at the mercy of a domestic court, foreign laws, unfamiliar traditions, doctrines, and established interpretations. Hence the need to submit the dispute to resolution by one or more arbitrators appointed by the parties from among global experts in their respective fields of business. The fundamental condition for such a solution is an arbitration agreement (the terms “arbitration court” and “arbitral tribunal” are often used interchangeably and refer to the same body resolving disputes through arbitration), included either in the initial agreement or in a separate agreement between the parties, which specifies the legal relationship from which the dispute arises or may arise. Obtaining an arbitration award does not, however, definitively conclude the case, but rather initiates the sometimes problematic issue of enforcing such an award in domestic courts. A foreign creditor who obtains an arbitration award that obligates a Polish entity to pay can generally expect its recognition and enforcement in a Polish domestic court.
More
